Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | HPGD | P15428 | 3/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3110577 | 0.82 | NPC1 (0.50) | ALDH1A1SMN1; SMN2HPGDHTTMAPT | |
| SCHEMBL7363630 | 0.79 | ALDH1A1 (0.70) | ALDH1A1SMN1; SMN2HPGDHTTMAPT | |
| SCHEMBL6914412 | 0.78 | ALDH1A1 (1.00) | ALDH1A1SMN1; SMN2HPGDHTTMAPT | |
| SCHEMBL15941304 | 0.78 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2HPGDHTTMAPT | |
| SCHEMBL9247222 | 0.78 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2HPGDHTTMAPT | |
| SCHEMBL834422 | 0.77 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2HPGDHTTMAPT | |
| SCHEMBL7358847 | 0.77 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2HPGDHTTMAPT | |
| SCHEMBL8583622 | 0.77 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2HPGDHTTMAPT | |
| SCHEMBL1276592 | 0.77 | ALDH1A1 (0.79) | ALDH1A1SMN1; SMN2HPGDHTTMAPT | |
| SCHEMBL5805320 | 0.77 | ALDH1A1 (0.87) | ALDH1A1SMN1; SMN2HPGDHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3184095-A1 | ADMINISTRATION UNITS COMPRISING POLYMORPH 1 OF 2-(2-METHYLAMINO-PYRIMIDIN-4-YL]-1H-INDOLE-5-CARBOXYLIC ACID [(S)-1-CARBAMOYL-2-(PHENYL-PYRIMIDIN-2-YL-AMINO)-ETHYL]-AMIDE | IP Gesellschaft für Management mbH (DE) | 2017-06-28 | — | — | EP | disclosed |
| EP-2805705-B1 | Packaging with one or more administration units comprising a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1 H-imidazol-4-yl)-propionic acid | IP GES FÜR MAN MBH (DE) | 2016-11-09 | — | — | EP | disclosed |
| EP-2805705-A1 | Packaging with one or more administration units comprising a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1 H-imidazol-4-yl)-propionic acid | IP Gesellschaft für Management mbH (DE) | 2014-11-26 | — | — | EP | disclosed |
| WO-2013084150-A1 | NOVEL CRYSTAL FORM OF (2S)-2-AMINO-3-HYDROXY-N-[2-METHOXY-2-[(1Z)-2-(3,4,5-TRIMETHOXYPHENYL)ETHENYL]PHENYL]PROPANAMIDE AND METHOD OF PREPARATION THEREOF | SANOFI (FR) | 2013-06-13 | — | — | WO | disclosed |
| EP-2562154-A1 | Method for preparing combretastatin | SANOFI (FR) | 2013-02-27 | — | — | EP | disclosed |
| EP-2348012-A1 | PROCESS FOR THE PREPARATION OF COMBRETASTATINE | Aventis Pharma S.A. (FR) | 2011-07-27 | — | — | EP | disclosed |
| US-20110124899-A1 | METHOD FOR PREPARING COMBRETASTATIN | SANOFI-AVENTIS (FR) | 2011-05-26 | — | — | US | disclosed |
| EP-2252572-A1 | METHOD FOR PREPARING COMBRETASTATIN | Sanofi-Aventis (FR) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009118474-A1 | METHOD FOR PREPARING COMBRETASTATIN | SANOFI-AVENTIS (FR) | 2009-10-01 | — | — | WO | disclosed |
| CN-1291970-C | Method for preparing combretastatins | AVENTIS PHARMA SA (FR) | 2006-12-27 | — | — | CN | disclosed |
| CN-1646476-A | Method for preparing combretastatins | AVENTIS PHARMA SA (FR) | 2005-07-27 | — | — | CN | disclosed |
| EP-1497255-A2 | METHOD FOR PREPARING COMBRETASTATINS | Aventis Pharma S.A. (FR) | 2005-01-19 | — | — | EP | disclosed |
| US-6759555-B2 | CONDENSING (3,4,5-TRIMETHOXYBENZYL)TRIPHENYLPHOSPHONIUM BROMIDE WITH 3-NITRO-4-METHOXYBENZALDEHYDE, REDUCING THE NITRO INTERMEDIATE TO FORM 2-METHOXY-5-(2-(3,4,5-TRIMETHOXYPHENYL)-ETHENYL)ANILINE | AVENTIS PHARMA S.A. (FR) | 2004-07-06 | — | — | US | disclosed |
| WO-2003084919-A3 | METHOD FOR PREPARING COMBRETASTATINS | AVENTIS PHARMA SA (FR) | 2004-04-08 | — | — | WO | disclosed |
| US-20030220404-A1 | Process for the preparation of combretastatins | AVENTIS PHARMA S.A. (FR) | 2003-11-27 | — | — | US | disclosed |
| WO-2003084919-A2 | METHOD FOR PREPARING COMBRETASTATINS | AVENTIS PHARMA S.A. (FR) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220404-A1 | Process for the preparation of combretastatins | TGFB2, HMGCR, TGFB1 | ALDH1A1 2753/4885SMN1; SMN2 1402/4885HPGD 1315/4885 |
| US-20110124899-A1 | METHOD FOR PREPARING COMBRETASTATIN | PCSK9, PCSK7, HMGCR | ALDH1A1 4433/4885SMN1; SMN2 3392/4885HPGD 3568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.